Descripción del proyecto
Información genética sobre la esclerosis múltiple
La esclerosis múltiple (EM o MS, por sus siglas en inglés) es una enfermedad autoinmunitaria que afecta a la vaina aislante de mielina de los axones del sistema nervioso central. En estudios pangenómico se han identificado diversas variantes genéticas asociadas al riesgo de padecer EM, principalmente vinculadas a genes de células inmunitarias. El equipo del proyecto SingleMS, financiado por el Consejo Europeo de Investigación, utilizará la ómica unicelular para investigar el papel activo de los oligodendrocitos, las células productoras de mielina. Centrará su atención en la accesibilidad de la cromatina y la expresión génica de estas variantes genéticas relacionadas con estos polimorfismos/variantes de un solo nucleótido. La caracterización del panorama transcriptómico y epigenómico de los oligodendrocitos humanos proporcionará importantes conocimientos sobre la patogenia de la EM, lo que allanará el camino para posibles estrategias terapéuticas.
Objetivo
Multiple sclerosis (MS) is a neurological disease characterized by autoimmune attack targeting oligodendroglia (OLG) in the central nervous system (CNS), and in particular their myelin, which ensheaths neuronal axons. Genome-wide association studies (GWAS) have led to the identification of hundreds of single-nucleotide polymorphisms (SNPs) and variants that are associated with MS risk. Many of these are located near genes associated with immune cells, indicating a key role for these cells in MS. Using single-cell omics approaches, we recently found that OLG present chromatin accessibility or express genes associated with some of these SNPs/variants, both in health and disease. Here, we hypothesize that OLG have a more active role in MS than previously anticipated, and therefore we will determine the function of MS SNPs/variants in OLG in the context of MS, using humanized mouse models, patient samples and new single-cell omics techniques recently developed in my group. We will 1) characterize in-depth the transcriptomic and epigenomic landscape of human and mouse OLG in the context of MS, to identify putative genes affected by the SNPs/variants; 2) perform CRISPR-guided editing of a cohort of the identified SNPs/variants in human OLG, and determine the consequences of the editing at a) an epigenomic and transcriptional level, linking specific SNPs/variants to their bona-fide target genes, and b) a functional level, by performing an array of functional assays targeting myelination, cell survival, and immune function, both in vitro and in humanized mouse chimeras in which engineered human OLG have been transplanted. We will use single-cell and spatial omics technologies, such as nanoCUT&Tag and spatial CUT&Tag, among others which we have recently developed in my research group. The results of this project will yield unique insights into the role of OLG and the identified SNPs/variants in MS, and thereby pave the way to novel therapeutic avenues for this disease.
Ámbito científico
Palabras clave
Programa(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régimen de financiación
HORIZON-ERC - HORIZON ERC GrantsInstitución de acogida
17177 Stockholm
Suecia